Jul 9, 2026 · 19 min · 9 segments
We are a decade into the CAR-T era, and what to long term outcomes look like with tisagenlecleucel in B-cell lymphomas? Orca-T is approved, an allogenic cocktail of stem & progenitor cells, Tregs, and…
John BazarHost
So what's notable about this is it is long-term follow-up of CAR-T, which is notable.
There's only 38 patients, 24 of whom had large B-cell lymphoma, 14 with follicular lymphoma.
And I'll just go through the abstract, and I'll tell you my first thought when I read this abstract.
I was kind of just scrolling in the morning, drinking coffee, and I just kind of skimmed the abstract on vacation, what my abstract thoughts were, and then went back and read the study going through it.
It tells me that exactly someone recurred at 5.4 years, a small sample size, but that does give some credence that this might be curative in some folks.
Which at this time, you know, filigree lymphoma, we've never thought was curative and for, Um, diffuse large B cell lymphoma or large cell B cell lymphoma.
If you didn't go to an auto transplant and relapse, we didn't think it was curative.
Um, 50%, um, sorry, 50% with follicular and, um, 17% was B cell lymphoma, 29% overall.
B-cell aplasia persisted in about half the patients, 44% that had a long-term response.
We kind of thought that it's encouraging that some folks were able to have normal B-cell recovery and able to have immune globulins produced on their own.
But I was like, you know, I was like, I bet a lot of these patients that had all this nonetheless mortality, this is probably a very heavily pre-treated population, more heavily pre-treated than our current CAR T patients.
And that ended up being the case, you know? So if we look at our baseline demographics, half of them had already had, based on demographics, those who had a long-term response, that's just 12.
So what's notable about this is it is long-term follow-up of CAR-T, which is notable.
There's only 38 patients, 24 of whom had large B-cell lymphoma, 14 with follicular lymphoma.
And I'll just go through the abstract, and I'll tell you my first thought when I read this abstract.
I was kind of just scrolling in the morning, drinking coffee, and I just kind of skimmed the abstract on vacation, what my abstract thoughts were, and then went back and read the study going through it.
It tells me that exactly someone recurred at 5.4 years, a small sample size, but that does give some credence that this might be curative in some folks.
Which at this time, you know, filigree lymphoma, we've never thought was curative and for, Um, diffuse large B cell lymphoma or large cell B cell lymphoma.
If you didn't go to an auto transplant and relapse, we didn't think it was curative.
Um, 50%, um, sorry, 50% with follicular and, um, 17% was B cell lymphoma, 29% overall.
B-cell aplasia persisted in about half the patients, 44% that had a long-term response.
We kind of thought that it's encouraging that some folks were able to have normal B-cell recovery and able to have immune globulins produced on their own.
But I was like, you know, I was like, I bet a lot of these patients that had all this nonetheless mortality, this is probably a very heavily pre-treated population, more heavily pre-treated than our current CAR T patients.
And that ended up being the case, you know? So if we look at our baseline demographics, half of them had already had, based on demographics, those who had a long-term response, that's just 12.
The rest of this transcript — segmented and speaker-labeled, so you land on the exact moment something was said
Search every transcript — by keyword, by phrase, or by meaning, across every show Radar indexes
Trends — what is surging across podcasts, measured against its own baseline
Alerts — when a name you follow appears in a newly indexed episode
No account is needed to search Radar.
